Herbesser Sr

Herbesser Sr is a prescription medication that contains the active ingredient diltiazem hydrochloride. It is formulated for oral administration, though the specific dosage form and strength are not disclosed in the available data. Classified as a calcium channel blocker, Herbesser Sr belongs to the therapeutic groups of antihypertensive and anti‑anginal agents and is marketed within the European Union. It is intended for use under medical supervision.

Herbesser Sr is prescribed for several cardiovascular conditions where reduction of blood pressure or myocardial oxygen demand is required.

- Management of hypertension in adults - Treatment of angina pectoris, including chronic stable angina - Rate control in patients with atrial fibrillation - Prevention of angina attacks during physical exertion - Adjunct therapy with other antihypertensive agents when monotherapy is insufficient

The safety profile of diltiazem hydrochloride includes both frequently observed and less common adverse reactions.

Common: - Headache - Flushing or warmth sensation - Peripheral edema, especially of the ankles - Dizziness or light‑headedness - Nausea or mild gastrointestinal upset - Fatigue or feeling of weakness

Serious: - Bradycardia or markedly slowed heart rate - Significant hypotension - Heart block or advanced atrioventricular conduction disturbances - Severe elevation of liver enzymes - Allergic reactions such as rash, angioedema, or anaphylaxis

Before initiating Herbesser Sr, clinicians should evaluate patient-specific factors and monitor for potential risks.

- Assess baseline blood pressure and heart rate - Avoid use in patients with severe sinus node dysfunction or high‑grade AV block - Use caution in patients with heart failure, particularly reduced ejection fraction - Monitor liver function tests during therapy - Adjust dose in hepatic impairment - Review concomitant medications that affect cardiac conduction - Consider potential risks in pregnancy or lactation, although the category is not established

Diltiazem interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Avoid: - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase diltiazem levels - Co‑administration with other non‑dihydropyridine calcium channel blockers can cause excessive cardiac depression - Combination with beta‑blockers may lead to profound bradycardia or atrioventricular block

Use with caution: - Co‑administration with digoxin may raise digoxin concentrations - Concurrent use with statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin) may increase statin exposure - Use with other antihypertensive agents may require dose adjustments to avoid hypotension